SUMMARY After the application in vitro of 14C amylopectin sulphate solution to frozen sections of human ulcer-bearing stomach, autoradiography demonstrates localization of amylopectin sulphate to the gastric surface. The affinity of amylopectin sulphate macromolecule for the gastric luminal surface would provide a substrate-bound pepsin inhibitor with a molecular sieve-like action to exclude proteolytic enzymes from the mucosal surface. This protective coating action may mimic the hypothetical role of endogenous gastric mucous substances and account for the action of amylopectin sulphate in human peptic ulcer.
Amylopectin sulphate (SN-263) (Cook, Eich, and Cammarata, 1963 ) is a synthetic water-soluble macromolecule (molecular weight 60 x 106) containing 1.6 sulphate ester groups per glucose unit that has a specific capacity to inhibit enzymatic digestion by pepsin in solution (Cook et al, 1963) . Its systematic development was based upon the hypothesis that reduced peptic digestion would promote healing of gastric and duodenal ulcers (Bianchi and Cook, 1964) . Controlled clinical trials of SN-263 in man have demonstrated its efficacy in accelerating healing of gastric ulcer (Zimmon, Miller, Cox, and Tesler, 1969) and preventing recurrence of duodenal ulcer (Sun and Ryan, 1970) . Although conceived as an enzyme inhibitor, recent investigations suggest an alternative mechanism of action based on substrate binding (Cammarata, Bianchi, and Fago, 1971) . To evaluate this possibility we have studied the localization of 14C in the human ulcer-bearing stomach.
Immediately after delivery of the distal stomach at the time of gastric resection for peptic ulcer, full-thickness 1 cm squares of the distal gastric lesser curvature within 9 cm of the pylorus were cut, orientated, and sectioned frozen at 3 microns in a cryostat. Unfixed frozen sections were mounted on numbered slides and stored at 0°C. Sections were processed unfixed or after 30 minutes' fixation in formol saline and five minutes' washing in water (three changes Cammarata et al (1971) indicating an important substrate binding action of SN-263. He showed that (1) in solution substrate bound SN-263 is a more efficient inhibitor of peptic proteolysis than pepsinbound SN-263; (2) SN-263 binds to the surface of heat-coagulated albumin and inhibits peptic proteolysis of the coated solid substrate; (3) a visible methylene blue: SN-263 complex is retained on dog gastric mucosa in vivo for four hours. The latter two observations have been confirmed in man (Zimmon, 1972; Zimmon and Cuy, 1972) . This study was designed to confirm the binding of SN-263 to human ulcer-bearing gastric mucosal surface and obviate the criticism that methylene blue: SN-263 complex might not behave identically to SN-263.
The sulphated glycoproteins found in normal gastric juice arise from salivary, bronchial, and oesophageal secretions that contaminate gastric juice as'adhering sulphated mucus' (Lambert, Andre, and Berard, 1971) . Thus, synthetic sulphated amylopectin behaves in a fashion similar to endogenous sulphated glycoproteins by coating the gastric mucosal surface. A role for endogenous sulphated glycoproteins in protecting gastroduodenal mucosa from peptic ulceration has been postulated on epidemiological grounds (Malhotra, 1970) . The binding of 14C SN-263 to the gastric mucosal surface revealed by autoradiography supports a mechanism of pepsin inhibition based upon surface coating. Particularly in the stomach and duodenum where continued secretion and emptying limit the persistence of luminal pepsin inhibitors, mucosal surface coating would prolong the duration of antipeptic action. The sulphated amylopectin macromolecules could form a mucin-like protective molecular sieve excluding proteolytic enzymes but passing smaller molecules. This protective coating action may mimic the hypothetical role of endogenous mucous substances and account for the observed therapeutic action of SN-263 in human peptic ulcer. This work was supported by the Veterans Administration. 14C SN-263 was kindly supplied by P. S. Cammarata, Ph.D, of G. D. Searle and Company, Skokie, Illinois.
